Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones

Progress in Neuro-psychopharmacology & Biological Psychiatry
Felice IasevoliAndrea de Bartolomeis

Abstract

The aim of this work was to compare achievements in milestones of community functioning in highly disabling psychiatric conditions, including treatment resistant schizophrenia (TRS), schizophrenia (responsive to antipsychotics), bipolar disorder, and anxiety/depressive diseases. Also, we investigated the predictors of community functioning outcomes across several domains. Among consecutive patients screened, 188 met inclusion criteria and 118 ultimately entered the study. Diagnosis of TRS was made by stringent criteria, including historic and perspective evaluations and excluding potential confounding factors. Achievements in functional milestones of everyday living were recorded. Performances in discrete cognitive tasks were assessed. The Positive and Negative Syndrome Scale, the Personal and Social Performance Scale, the Drug Attitude Inventory-10, and the Quality of Life Enjoyment and Satisfaction Questionnaire were administered. TRS patients showed the highest impairment in community functioning among diagnostic groups. TRS was found to have more severe psychopathology, more impaired cognitive functioning, and poorer psychosocial adjustment compared to all the other groups. In the whole sample, the main predictors of commun...Continue Reading

References

Jan 1, 1990·Schizophrenia Bulletin·H Y Meltzer
Mar 1, 1985·The British Journal of Psychiatry : the Journal of Mental Science·T KolakowskaB M Mandelbrote
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Nov 5, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J A LiebermanB J Kinon
Oct 30, 1998·Journal of Psychiatric Research·B B Sheitman, J A Lieberman
Feb 23, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·E StipP Liddle
Dec 18, 2001·Biological Psychiatry·R R Conley, D L Kelly
Apr 3, 2003·Clinical Neuropharmacology·Vladimir Lerner
Apr 2, 2004·The American Journal of Psychiatry·Franca CentorrinoRoss J Baldessarini
Nov 4, 2004·CNS Drugs·A George Awad, Lakshmi N P Voruganti
Jan 18, 2005·Schizophrenia Research·Joseph M PierreDavid G Saunders
Mar 3, 2005·The American Journal of Psychiatry·Nancy C AndreasenDaniel R Weinberger
Dec 6, 2005·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·A RossiUNKNOWN (For the EQUIP group)
Mar 4, 2006·The American Journal of Psychiatry·Robert RosenheckUNKNOWN CATIE Study Investigators Group
Jul 11, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtRolf R Engel
Oct 4, 2006·Journal of Psychiatric Research·Christopher R BowiePhilip D Harvey
Dec 14, 2006·Schizophrenia Bulletin·Dwight DickinsonJames M Gold
May 12, 2007·Schizophrenia Bulletin·Philip D HarveyAlan S Bellack
Apr 19, 2008·Journal of the International Neuropsychological Society : JINS·Winnie W LeungPhilip D Harvey
May 17, 2008·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Simona AnselmettiRoberto Cavallaro
Jun 3, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Carol PatonUNKNOWN POMH-UK project team
Jun 16, 2009·Schizophrenia Bulletin·Feea R LeifkerPhilip D Harvey
Oct 1, 2009·Human Psychopharmacology·Alessandro RossiUNKNOWN Risperidone Long-Acting Trial Investigators (R-LAI)
Dec 4, 2009·Schizophrenia Bulletin·Lisa B DixonUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
Nov 19, 2010·Schizophrenia Bulletin·Philip R SzeszkoDelbert G Robinson
May 17, 2011·The American Journal of Psychiatry·Philip D HarveyThomas L Patterson
May 31, 2011·Schizophrenia Research·Samir SabbagPhilip D Harvey
Jul 20, 2011·BMC Psychiatry·Michael ObermeierFlorian Seemüller
Oct 5, 2011·Psychiatric Services : a Journal of the American Psychiatric Association·Mark OlfsonSteven C Marcus
Sep 8, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Oliver D HowesDavid Taylor
Oct 5, 2012·The American Journal of Psychiatry·Arsime DemjahaOliver D Howes
Mar 20, 2013·Schizophrenia Research·Cynthia Z BurtonElizabeth W Twamley
Apr 4, 2013·The British Journal of Psychiatry : the Journal of Mental Science·Mary J De SilvaVikram Patel

❮ Previous
Next ❯

Citations

Mar 2, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Philip D Harvey, Jennifer B Rosenthal
Feb 27, 2019·Health Technology Assessment : HTA·Anthony P MorrisonDavid Kingdon
May 29, 2018·European Archives of Psychiatry and Clinical Neuroscience·G FondUNKNOWN FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group
Mar 14, 2019·Frontiers in Psychiatry·Paola BozzatelloPaola Rocca
Apr 9, 2019·International Journal of Methods in Psychiatric Research·Linus JönssonLouise Watson
Sep 29, 2019·International Journal of Molecular Sciences·Aline HajjSouheil Hallit
Dec 9, 2017·Early Intervention in Psychiatry·Henriette T HorsdalChristiane Gasse
May 26, 2018·Therapeutic Advances in Drug Safety·Domenico De BerardisMassimo Di Giannantonio
Nov 30, 2019·The Clinical Neuropsychologist·Briana D CassettaIvan J Torres
Jan 29, 2021·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Domenico De BerardisMassimo Di Giannantonio
Dec 22, 2020·Journal of Clinical Psychopharmacology·Graham BlackmanJames MacCabe
Jul 15, 2021·Molecular Psychiatry·Oliver D HowesToby Pillinger
Jul 26, 2021·Journal of Psychiatric Research·Marco SpangaroRoberto Cavallaro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here